Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Sarcoglycan, the heart, and skeletal muscles: new treatment, old drug?
Jeffrey A. Towbin, Neil E. Bowles
Jeffrey A. Towbin, Neil E. Bowles
Published January 15, 2001
Citation Information: J Clin Invest. 2001;107(2):153-154. https://doi.org/10.1172/JCI11998.
View: Text | PDF
Commentary

Sarcoglycan, the heart, and skeletal muscles: new treatment, old drug?

  • Text
  • PDF
Abstract

Authors

Jeffrey A. Towbin , Neil E. Bowles

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
Proteins of the sarcomere, cytoskeleton, sarcolemma, and ECM of muscle, ...
Proteins of the sarcomere, cytoskeleton, sarcolemma, and ECM of muscle, which are connected. Mutations in δ-sarcoglycan, dystrophin, actin, desmin, and lamin A/C are known to cause DCM. All of these genes also cause forms of skeletal myopathy when mutated. Mutations in any of the genes illustrated could potentially cause DCM and/or skeletal myopathy, forming the basis of the “final common pathway.” Signaling pathways (such as nNos) interacting with these proteins are likely to modify the phenotype.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts